@oncothor.bsky.social
🇮🇸 🇺🇸 Medical Oncologist/Educator, NET/GI/CUP enthusiast. Husband/dad x4 (bad dad jokes). Cyclist. Avant gardener. Professor of Oncology, Mayo Clinic. Tweets mine, not endorsement/advice. https://tinyurl.com/22w4kxjj #NETsSky #MedSky #OncSky
Are you an oncologist with interest in GI cancer? If so, are you interested in joining a growing academic GI Oncology practice in Rochester, MN? We have 13 GI oncs with additional 3 joining soon and still growing 😀
We are hiring!
PM me if interested.
jobs.mayoclinic.org/job/rocheste...
Adjuvant immunotherapy (camrelizumab) and CRT following resection of gall bladder cancer and extrahepatic cholangiocarcinoma. Small randomized trial, interesting findings in need of further validation.
jamanetwork.com/journals/jam...
Want a quick update in medical oncology on July 19 (with some heme updates in the mix)...? If so, we have the course for you! I can promise excellent content/speakers and there is a livestream (virtual) option too for those who cannot attend in person.
ce.mayo.edu/hematology-a...
The next frontier in radioligand therapy (RLT), radioligand-antibody drug conjugates...? Interesting data targeting TROP2 and HER2 in xenograft mouse models with orthotopic breast tumors. I am certainly keeping an eye on how this develops...
aacrjournals.org/mct/article/...
PRRT is a very effective for well-differentiated NETs but associated with a low risk of treatment related myeloid neoplasms ( t-MN ). If you are interested in learning more, this is the review for you...
erc.bioscientifica.com/view/journal...
Lot to unpack from the excellent NORDIC NEC2.
- ORR: 31% for NEC (mostly plat/eto) - this is NOT SCLC
- ORR: 27% for G3 NETs (mostly TMZ-based)
- Immediate progression: 41% of NECs, 21% G3 NETs
- PFS: 3.4 m NEC; 7.4 G3 NET
NECs are really bad cancers!
www.nature.com/articles/s41...
Did you just wake up thinking how great it wold be to have a new review on extrahepatic cholangiocarcinoma...? If so, you are in luck. Here it is, courtesy of EASL
www.sciencedirect.com/science/arti...
Are you looking for a short update course in oncology this summer. Like a day-long course that covers recent data presented at ASCO and other recent meetings and publications. If so, we sure have the course for you. Online option also. @mayocliniccancer.bsky.social
ce.mayo.edu/hematology-a...
It is not all about tumor shrinkage after PRRT. In this NETTER-1 analysis, PFS and OS were not different in patients where tumor shrinkage was seen. Not a new observation but a topic I discuss every week with patients. Benefits can be seen w/o high ORR...
onlinelibrary.wiley.com/doi/10.1002/...
Wishing you had access to new and updated guidelines on MEN1...? Worry not, this team has you covered.
www.sciencedirect.com/science/arti...
Time to rethink our approach to NET grading and use whole slide analysis (WSA) in addition to hotspot analysis (HSA) when assigning tumor grade using Ki-67? It certainly seems so.... @IHC_guy
www.modernpathology.org/article/S089...
Trying to summarize nuanced treatment decisions in one slide... What to do with small NF-pNETs? Who to observe? When to intervene...? What am I missing/getting wrong...?
09.04.2025 13:29 — 👍 4 🔁 1 💬 0 📌 0
Looking for a review on genomics in cancers of unknown primary...? Here you have it!
As I have said before, every CUP patient seen in the Mayo CUP Clinic will have genomic testing. It is a somewhat surprisingly target-rich malignancy.
www.sciencedirect.com/science/arti...
DLL3 expression in high-grade NENs? Not rare at all! Check out this large study. 64% of NECs pos, 42% lung NETs, but only 5% GEPNETs are pos with the exception of G3 NETs which are 20% mod or strongly pos. DLL3-directed trials coming but not for G3 NETs.
link.springer.com/article/10.1...
What's happened in imaging for CUPs in the last decades, where are we now and where might we be going...? Very good overview with detailed tables of detection rates for different modalities. The stuff you need for your next talk or paper on CUP...
academic.oup.com/bjr/advance-...
Are you interested in learning more about the management of small panc NETs and how molecular analysis may predict outcomes? If so, I have just the right paper for you... 😀 Thanks to @PancPathologist, Anna Vera Verschuur, C. Heaphy, L. Brosens et al.
erc.bioscientifica.com/view/journal...
In case you needed a reminder of the not-so-predictable somatostatin receptor expression of lung NETs, here you have it...
Keep in mind that only 44% had uniformly positive SSTR expression and some have none at all like this patient.
jnm.snmjournals.org/content/64/1...
CUP oncology is increasingly precision oncology. Patient in 60s, extensive BRG-1 deficient undifferentiated poorly diff carcinoma of unknown primary. Near complete but not durable response to docetaxel/cisplatin/pembro followed by durable response to adagrasib for KRAS G12C mut.
21.03.2025 01:13 — 👍 0 🔁 0 💬 0 📌 0
Similar findings here...
And did I mention you should seek out and enroll on SWOG S2012...? Just wanted to be sure you understood that epNECs are NOT SCLC and we have a trial ongoing.
onlinelibrary.wiley.com/doi/10.1111/...
Should we routinely add ICIs to chemo (platinum/etoposide) in extrapulmonary NECs? I think no. Yes, I realize the outcomes in advanced NEC are poor but we simply do not have the data yet. No benefit in this retrospective study. Enroll on SWOG S 2012!!!
academic.oup.com/oncolo/artic...
He convinced me…. Temps in the mid 70s yesterday and now low 30s and flurries. Gotta love the early spring in Minnesota 😂
15.03.2025 16:34 — 👍 3 🔁 0 💬 0 📌 0
Why are you answering emails and working on a book chapter on a Saturday…? We could be out playing.
15.03.2025 15:16 — 👍 18 🔁 0 💬 3 📌 0
If you were thinking of how nice it would be to have a recent review on functional NETs, you got one here courtesy of Francesca Spada and team. Excellent introduction to the fascinating world of functional NETs.
www.sciencedirect.com/science/arti...
Still a little confused on the difference between grade and differentiation in panc NETs...? Need a quick primer on the pathology of pNETs including the genetic/molecular alterations. If so, Dr's. Rindi and Inzani have you covered.
meridian.allenpress.com/aplm/article...
It may still be dull, gray and brown but spring is in the air in Minnesota. Unseasonably warm day, the fields are freshly tilled and I am off today. What better than a good dose of gravel riding. Just what the doctor ordered…
12.03.2025 23:36 — 👍 1 🔁 0 💬 0 📌 0
Not sure about you but I find this depressing..
Of 5059 respondents, 47.7% reported fewer than 15 days of vacation in the last year, with 9.8% taking 5 or fewer days.
Personally, I take 5-6 weeks off every year and rarely log into the EMR or do work.
www.mayoclinicproceedings.org/article/S002...
Look, I am posting a non-NET, non-CUP paper! Weekend warrior exercise does seem to have similar protective benefits as more regular exercise throughout the week. Very large study from the UK Biobank. What about us who do both...? 😀
www.mayoclinicproceedings.org/article/S002...
No wonder I am gently nudging my teenage daughters to study in Europe (they are dual citizens with Europe open) and even better, permanently settle there, ideally in one of the Nordic countries...
28.02.2025 13:26 — 👍 1 🔁 0 💬 0 📌 0
PRRT + PARP inhibitors in advanced NETs? To date, no trials have convincingly shown that PRRT + drug X (whatever that may be) is better than PRRT alone. The addition of PARPi seems to add little early toxicity but larger trials needed to show efficacy.
jnm.snmjournals.org/content/earl...
